https://www.aigom.it/wp-content/uploads/2025/04/Screenshot-2025-04-11-100128-2.png428300Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-11 08:12:362025-04-11 08:17:3916 GIUGNO 2025-AIGOM LE NOVITA’ DA CHICAGO 2025: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA
https://www.aigom.it/wp-content/uploads/2025/04/8-APRILE.png1301960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-08 07:56:242025-04-08 07:56:24CAPItello-291 STUDY GROUP. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2025/04/1aprile.png15431073Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-01 08:32:102025-04-01 08:32:10FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/03/25.3.png1215960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-25 09:16:212025-03-25 09:16:21PHASE II EFFICACY AND SAFETY OF 80 MG OSIMERTINIB IN PATIENTS WITH LEPTOMENINGEAL METASTASES ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (BLOSSOM).
https://www.aigom.it/wp-content/uploads/2025/03/IMM18.3.png1136960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-18 08:35:452025-03-18 08:35:45OSIMERTINIB AFTER CHEMORADIOTHERAPY IN STAGE III EGFR-MUTATED NSCLC.
https://www.aigom.it/wp-content/uploads/2025/03/LOC.11.3.png1342960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-11 08:47:002025-03-11 08:47:00FIRST-LINE NIVOLUMAB PLUS RELATLIMAB VERSUS NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA: AN INDIRECT TREATMENT COMPARISON USING RELATIVITY-047 AND CHECKMATE 067 TRIAL DATA.
https://www.aigom.it/wp-content/uploads/2025/03/loc14-15-3.png706748Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 09:23:052025-03-17 08:45:32NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 MARZO 2025
https://www.aigom.it/wp-content/uploads/2025/03/art4.3.png1242960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-03-04 08:49:132025-03-04 08:58:47FINAL, 10-YEAR OUTCOMES WITH NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA.
https://www.aigom.it/wp-content/uploads/2025/02/Screenshot-2025-02-27-094112.png680749Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-02-27 09:07:102025-03-04 09:27:03SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 14-SABATO 15 FEBBRAIO 2025
